Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

530 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators.
Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, Armstrong PW, Topol EJ, Califf RM. Berkowitz SD, et al. Circulation. 1997 Jun 3;95(11):2508-16. doi: 10.1161/01.cir.95.11.2508. Circulation. 1997. PMID: 9184581
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Boersma E, et al. Among authors: simoons ml. Circulation. 2000 Jun 6;101(22):2557-67. doi: 10.1161/01.cir.101.22.2557. Circulation. 2000. PMID: 10840005 Clinical Trial.
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
Tung CY, Granger CB, Sloan MA, Topol EJ, Knight JD, Weaver WD, Mahaffey KW, White H, Clapp-Channing N, Simoons ML, Gore JM, Califf RM, Mark DB. Tung CY, et al. Among authors: simoons ml. Circulation. 1999 Jan 26;99(3):370-6. doi: 10.1161/01.cir.99.3.370. Circulation. 1999. PMID: 9918523
Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.
Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Topol E, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators. Ottervanger JP, et al. Among authors: simoons ml. Circulation. 2003 Jan 28;107(3):437-42. doi: 10.1161/01.cir.0000046487.06811.5e. Circulation. 2003. PMID: 12551868 Clinical Trial.
Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA.
Lenderink T, Boersma E, Heeschen C, Vahanian A, de Boer MJ, Umans V, van den Brand MJ, Hamm CW, Simoons ML; CAPTURE Investigators. Lenderink T, et al. Among authors: simoons ml. Eur Heart J. 2003 Jan;24(1):77-85. doi: 10.1016/s0195-668x(02)00322-6. Eur Heart J. 2003. PMID: 12559939 Clinical Trial.
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML; Fibrinogen Receptor Occupancy Study (FROST) Investigators. Akkerhuis KM, et al. Among authors: simoons ml. Eur Heart J. 2000 Dec;21(24):2042-55. doi: 10.1053/euhj.2000.2309. Eur Heart J. 2000. PMID: 11102255 Clinical Trial.
530 results